Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Change in Accured Expenses (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Change in Accured Expenses data on record, last reported at -$89967.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 64.95% year-over-year to -$89967.0; the TTM value through Sep 2025 reached -$229708.0, down 27675.99%, while the annual FY2024 figure was $180934.0, N/A changed from the prior year.
  • Change in Accured Expenses reached -$89967.0 in Q3 2025 per COEP's latest filing, up from -$186238.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $180934.0 in Q4 2024 and bottomed at -$465491.0 in Q4 2021.
  • Average Change in Accured Expenses over 5 years is -$35308.2, with a median of $2624.0 recorded in 2021.
  • The widest YoY moves for Change in Accured Expenses: up 21620.77% in 2024, down 30716.57% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$465491.0 in 2021, then surged by 61.72% to -$178178.0 in 2022, then surged by 100.47% to $833.0 in 2023, then soared by 21620.77% to $180934.0 in 2024, then crashed by 149.72% to -$89967.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$89967.0 in Q3 2025, -$186238.0 in Q2 2025, and -$134437.0 in Q1 2025.